# Niacinamide

> Niacinamide is vitamin B3 in its amide form, different from niacin, which causes flushing through prostaglandin release. Niacinamide is non-flushing, demonstrates mast cell stabilizing effects in lab models relevant to MCAS, supports NAD+ production, and shows pro-collagen activity in dermal fibroblasts at supplemental doses. ZebraThrive uses 50 mg in the AM stack.

**Page:** https://www.wellnessforzebras.com/ingredients/niacinamide
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 50 mg AM
**Form used:** Niacinamide (amide form, USP grade, fermentation-free)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- Non-flushing B3 form (niacin's flush is prostaglandin-driven and reads as a controlled mast cell event)
- Historical mast cell stabilizing effects in lab models (Bekier 1974, 1975)
- Pro-collagen activity in dermal fibroblasts at supplemental doses
- Conservative 50 mg dose stays below the methylation-driven histamine threshold flagged in human data

## What it is

Niacinamide is vitamin B3 in its amide form - different from niacin, which causes flushing through prostaglandin release.

## Why we include it

Niacinamide is non-flushing and historically demonstrates mast cell stabilizing effects in lab models. It supports skin barrier function, NAD+ production, and pro-collagen activity in dermal fibroblasts at concentrations achievable from supplementation.

## Plain-language summary

Niacinamide is vitamin B3 in its amide form - different from niacin, which causes flushing through prostaglandin release. Niacinamide is non-flushing and historically demonstrates mast cell stabilizing effects in lab models. It supports skin barrier function, NAD+ production, and pro-collagen activity in dermal fibroblasts at concentrations achievable from supplementation. For the triad specifically, we use a conservative 50 mg dose because human data shows higher doses can transiently raise plasma histamine through methylation pathway competition - important to know for an MCAS-aware formulation. At 50 mg, niacinamide hits the benefit profile without the histamine concern.

## Mechanism

Niacinamide is vitamin B3 in its amide form - different from niacin, which causes flushing through prostaglandin release. Niacinamide is non-flushing and historically demonstrates mast cell stabilizing effects in lab models. It supports skin barrier function, NAD+ production, and pro-collagen activity in dermal fibroblasts at concentrations achievable from supplementation. For the triad specifically, we use a conservative 50 mg dose because human data shows higher doses can transiently raise plasma histamine through methylation pathway competition - important to know for an MCAS-aware formulation. At 50 mg, niacinamide hits the benefit profile without the histamine concern.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Niacinamide has mixed evidence in MCAS - and we navigate it carefully. Older lab studies (Bekier 1974, 1975) showed niacinamide inhibits mast cell degranulation similarly to cromolyn, which is favorable. But a 2013 human study showed 100 mg raised plasma histamine through methylation pathway competition, which is unfavorable. We dose at 50 mg specifically to capture the mast-cell-stabilizing side without crossing into the methylation/histamine threshold. We also include methylfolate and methylated B12 to keep the methyl donor pool topped up. A conservative middle path that respects what the human data actually shows.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

For hEDS, niacinamide contributes pro-collagen activity in dermal fibroblasts - part of the broader connective tissue support stack, though not a hero ingredient at our 50 mg dose. The bigger contribution is NAD+ pathway support alongside NR, which feeds the sirtuin-MMP axis (SIRT1/SIRT6 activation reduces MMP-1 and MMP-9 expression in dermal fibroblasts and tenocytes). At our conservative dose, niacinamide is a foundation B-vitamin for hEDS rather than a targeted intervention. The targeted ECM-protective work happens through the polyphenols and direct MMP-modulating ingredients elsewhere in the formulation.

### POTS (Postural Orthostatic Tachycardia Syndrome)

Niacinamide's POTS relevance is mitochondrial: NAD+ pathway support for the chronic fatigue that frequently shadows POTS (many POTS patients also meet ME/CFS criteria). Niacinamide alongside NR provides broader B3 coverage for mitochondrial energy production. The 50 mg dose is deliberately conservative enough not to push methylation balance, which matters because methylation competition can affect catecholamine metabolism - and catecholamine handling is already disordered in POTS. The conservative dose is itself part of the POTS-friendliness, alongside the methylation-supporting B-vitamins that anchor that pathway.

## Why this form

**Selected form:** Niacinamide (amide form, USP grade, fermentation-free)

We use niacinamide (the amide form), not niacin, and at a deliberately conservative 50 mg per day. Niacin causes flushing through prostaglandin release from Langerhans cells - that 'niacin flush' is uncomfortable and can be a problem for sensitive populations. Niacinamide is the non-flushing form. We chose 50 mg specifically because a 2013 human study showed 100 mg raised plasma histamine at 5 hours through methylation depletion - a real consideration for MCAS patients. Half that dose delivers the niacinamide benefit profile without crossing the methylation/histamine threshold.

## Evidence summary

### Methylation/Histamine Dose Constraint

Human data establishes a methylation-competition mechanism by which higher niacinamide doses raise plasma histamine through draw on the methyl donor pool that HNMT also uses. This is the dose-ceiling rationale for our conservative 50 mg/day formulation.

- [1] **Tian YJ et al., "Excess nicotinamide increases plasma serotonin and histamine levels".** Design: Human PK study. Finding: 100 mg of niacinamide raised plasma histamine at 5 hours after a single dose; mechanism attributed to methyl donor competition (HNMT and NNMT share the same SAM-dependent methyl pool). PMID: 23426511.
- [2] **Loring HS, Thompson PR, "Kinetic Mechanism of Nicotinamide N-Methyltransferase".** Design: Enzyme kinetics study, NNMT mechanism. Finding: Characterized the kinetic mechanism by which NNMT (nicotinamide N-methyltransferase) catalyzes the SAM-dependent methylation of nicotinamide, establishing the biochemical basis for methyl pool depletion at high niacinamide doses. PMID: 30148963.

### Safety and Hepatotoxicity Ceiling

Niacinamide has been extensively reviewed for high-dose safety in the diabetes-prevention literature. Reversible hepatotoxicity has been reported above 3 g/day; minor abnormalities of liver enzymes can occur infrequently. Our 50 mg dose sits two orders of magnitude below the safety threshold.

- [3] **Knip M et al., "Safety of high-dose nicotinamide: a review".** Design: Literature review of high-dose nicotinamide trials. Finding: Therapeutic index is wide; reversible hepatotoxicity reported at doses above 3 g/day in animals and humans; minor liver enzyme abnormalities infrequent at typical study doses; no evidence of teratogenicity or oncogenicity. PMID: 11126400.
- [4] **Cosmetic Ingredient Review Expert Panel, "Final report of the safety assessment of niacinamide and niacin".** Design: Comprehensive safety review. Finding: Both niacinamide and niacin are non-toxic at levels considerably higher than typical supplemental or cosmetic use; oral bioavailability ~100%, half-life 7-9 hours at higher doses. PMID: 16596767.

### NAD+ Pathway Coverage Alongside NR

Niacinamide functions as a complementary B3 form alongside Nicotinamide Riboside for NAD+ pathway support. Recent mechanistic work documents the NAD-boosting class as a mast cell stabilizing pathway through SIRT6 signaling.

- [5] **Kim DJ et al., "NAD-boosting molecules suppress mast cell degranulation and anaphylactic responses in mice".** Design: Mouse + human cord blood-derived mast cell + cell models. Finding: NAD-boosting molecules (NMN and NR) suppress mast cell degranulation through SIRT6 pathway; the same NAD+ axis niacinamide contributes to at a smaller magnitude. PMID: 35547746.

## Safety

**Side effects:** Excellent safety at the 50 mg dose. Niacinamide is non-flushing (unlike niacin). Very high doses (>3 g/day) have hepatotoxicity concerns; our dose is 50x below that level. No reported acute side effects in healthy populations at supplement doses.

**Interactions:** At 50 mg, no clinically meaningful interactions with the standard POTS, MCAS, or hEDS medication stack. Theoretical methylation competition with high doses (>500 mg) of other methylation-dependent compounds; the formulation includes methylfolate and methylated B12 to support methyl group availability. Mention to your prescriber if you take additional high-dose B3 separately.

**Excipients to avoid:** Fermentation-derived sources, Artificial colors, Magnesium stearate

**Excipients that are safe:** HPMC capsules, Rice flour, Cellulose

## Frequently asked questions

### Niacinamide vs niacin - what's the difference?

Both are vitamin B3, but they're chemically distinct and act differently. Niacin (nicotinic acid) activates GPR109A receptors on skin Langerhans cells, triggering a prostaglandin release that causes the classic 'niacin flush' - uncomfortable warmth, redness, sometimes itching. Niacinamide (nicotinamide) doesn't activate GPR109A, so no flushing. For MCAS-aware formulations, niacinamide is the only defensible choice - niacin's prostaglandin-driven flush is essentially a controlled mast cell event.

### Why is the dose only 50 mg?

Because of a 2013 human study (Tian et al.) showing 100 mg of niacinamide raised plasma histamine at 5 hours after a single dose. The mechanism is methylation competition: niacinamide gets cleared through methylation, drawing on the same methyl donor pool that HNMT needs to break down histamine. At 50 mg, the methylation draw is modest and the histamine concern doesn't materialize. We made the trade - slightly lower NAD+ contribution for a clean MCAS safety profile.

### Does niacinamide actually help with collagen?

In dermal fibroblast studies, yes, niacinamide supports pro-collagen activity at concentrations achievable from oral dosing. At our 50 mg dose the connective tissue contribution is modest; the bigger value is NAD+ pathway support alongside NR and general B-vitamin coverage. It's a supporting cast ingredient at this dose, not a hero player.

### What's niacinamide's role alongside NR?

NR (nicotinamide riboside) is the more efficient NAD+ precursor - it raises blood NAD+ levels more reliably than niacinamide does. Niacinamide at 50 mg provides additional NAD+ pathway support and a different downstream metabolite profile, including the historical mast cell stabilization data from older lab studies. Think of niacinamide as broad B3 coverage and NR as targeted NAD+ raise. We include both because they cover different aspects of the vitamin B3 family at low cumulative cost.

## References

[1] Tian YJ et al.. (2013). Excess nicotinamide increases plasma serotonin and histamine levels. PMID: 23426511. https://pubmed.ncbi.nlm.nih.gov/23426511/
[2] Loring HS, Thompson PR. (2018). Kinetic Mechanism of Nicotinamide N-Methyltransferase. PMID: 30148963. https://pubmed.ncbi.nlm.nih.gov/30148963/
[3] Knip M et al.. (2000). Safety of high-dose nicotinamide: a review. PMID: 11126400. https://pubmed.ncbi.nlm.nih.gov/11126400/
[4] Cosmetic Ingredient Review Expert Panel. (2005). Final report of the safety assessment of niacinamide and niacin. PMID: 16596767. https://pubmed.ncbi.nlm.nih.gov/16596767/
[5] Kim DJ et al.. (2022). NAD-boosting molecules suppress mast cell degranulation and anaphylactic responses in mice. PMID: 35547746. https://pubmed.ncbi.nlm.nih.gov/35547746/